These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 19073384

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
    Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, Rodríguez-Frias F, Falco V, Curran A, Imaz A, Villar del Saz S, Ocaña I, Esteban R, Pahissa A.
    Clin Infect Dis; 2009 Apr 15; 48(8):1152-9. PubMed ID: 19275492
    [Abstract] [Full Text] [Related]

  • 23. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.
    Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC.
    Liver Int; 2009 Nov 15; 29(10):1485-93. PubMed ID: 19602134
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
    Bräu N.
    Semin Liver Dis; 2005 Feb 15; 25(1):33-51. PubMed ID: 15731996
    [Abstract] [Full Text] [Related]

  • 26. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H, Tahan V, Canbakan B, Uraz S, Ulger Y, Ozaras R, Tabak F, Mert A, Ozbay G.
    Neth J Med; 2008 May 15; 66(5):191-5. PubMed ID: 18490796
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y, Tanaka E, Orii K, Rokuhara A, Ichijo T, Yoshizawa K, Kiyosawa K.
    J Gastroenterol Hepatol; 2000 Nov 15; 15(11):1292-7. PubMed ID: 11129224
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Martín-Carbonero L, Puoti M, García-Samaniego J, De Luca A, Losada E, Quinzan G, Bruno R, Mariño A, González M, Núñez M, Soriano V.
    J Viral Hepat; 2008 Oct 15; 15(10):710-5. PubMed ID: 18637070
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center.
    Maida I, Soriano V, Ramos B, Ríos P, González-Lahoz J, Núñez M.
    HIV Clin Trials; 2005 Oct 15; 6(6):329-36. PubMed ID: 16452066
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández-Carbia A, González-Lassalle E, Salgado-Mercado R, Marxuach-Cuétara AM.
    J Clin Virol; 2007 Jan 15; 38(1):32-8. PubMed ID: 17064957
    [Abstract] [Full Text] [Related]

  • 35. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.
    del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, Girón JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Pineda JA.
    AIDS; 2008 May 11; 22(8):923-30. PubMed ID: 18453851
    [Abstract] [Full Text] [Related]

  • 36. Response to anti-HCV therapy in HIV-HCV-coinfected patients: does the lipid profile really have an effect?
    Petit JM, Carrat F, Duong M, Halfon P, Duvillard L, Bani-Sadr F, Chavanet P, Cacoub P, Piroth L.
    Antivir Ther; 2010 May 11; 15(5):797-800. PubMed ID: 20710062
    [Abstract] [Full Text] [Related]

  • 37. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C, ANRS HCO2 RIBAVIC Study Team.
    JAMA; 2004 Dec 15; 292(23):2839-48. PubMed ID: 15598915
    [Abstract] [Full Text] [Related]

  • 38. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
    Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, Schiano T, Sulkowski M, Dieterich D, Branch A.
    HIV Med; 2014 Feb 15; 15(2):108-15. PubMed ID: 24025147
    [Abstract] [Full Text] [Related]

  • 39. Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients.
    Soriano V, Pérez-Olmeda M, Ríos P, Núñez M, García-Samaniego J, González-Lahoz J.
    AIDS Res Hum Retroviruses; 2004 Apr 15; 20(4):351-3. PubMed ID: 15157353
    [Abstract] [Full Text] [Related]

  • 40. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.
    Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, Perelson AS.
    J Infect Dis; 2003 Nov 15; 188(10):1498-507. PubMed ID: 14624375
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.